Brain Cancer | Specialty

Dr. Lukas on Immunotherapy in Glioblastoma

October 26th 2016

Rimas V. Lukas, MD, associate professor of Neurology, director, Medical Neuro-Oncology, University of Chicago Medicine, discusses some of the exciting advances recently seen with immunotherapy in the treatment of patients with glioblastoma

Computer Simulation Helps Plan Transducer Placement in Glioblastoma

October 13th 2016

For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.

NYU Scientist Sees Hope Peeking Through Gloom of Glioblastoma

October 4th 2016

Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.

Wearable Therapy Making Inroads in Oncology

September 30th 2016

Two headgear items, a system of applying electromagnetic currents to patients with glioblastoma and a cooling cap for individuals undergoing chemotherapy for breast cancer, are early entries in the field.

Early Potential Seen With Immunotherapy in Glioblastoma, But Questions Remain

August 26th 2016

David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

August 19th 2016

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Models Pave the Way for Improved Outcomes in Medulloblastoma

August 16th 2016

To discover targeted therapies for the more common and severe types of medulloblastoma, a laboratory at Sanford Burnham Prebys Medical Discovery Institute has led efforts to develop genetically engineered mouse models and patient-derived xenografts for studying the molecular basis of the disease.

Dr. van den Bent on Adjuvant Temozolomide in Anaplastic Glioma

July 27th 2016

Martin J. Van Den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherland, discusses the results of an interim analysis of the randomized phase III CANTON trial, which investigated concurrent and adjuvant temozolomide in patients with anaplastic glioma without a 1p/19q co-deletion.

Pembrolizumab/Bevacizumab Combo Passes Safety Test in Recurrent Glioblastoma

June 8th 2016

An immunotherapy/antiangiogenesis combination proved to be safe and tolerable for patients with recurrent glioblastoma, preliminary data from an ongoing trial showed.

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

June 7th 2016

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

Survival in Recurrent GBM Surpasses Historical Results with Gene Therapy

June 6th 2016

A novel antiangiogenic gene therapy, added to bevacizumab, led to significantly better overall survival in recurrent glioblastoma multiforme compared with historical patients treated with bevacizumab alone, a small phase II trial showed.

Adding Temozolomide to Radiotherapy Is Effective and Tolerable in Older Adults With Glioblastoma

June 5th 2016

Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.

Nivolumab Safe, Effective in Early Stage Glioblastoma Study

June 5th 2016

Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.

Temozolomide Trial Shows Improved 5-Year Survival Rates in Anaplastic Glioma

June 4th 2016

Results from a phase III trial investigating the benefit of adjuvant temozolomide in combination with radiation therapy has the potential to be practice changing for a rare type of brain cancer.

Oncolytic Poliovirus Receives Breakthrough Designation for Glioblastoma

May 16th 2016

The recombinant oncolytic poliovirus PVS-RIPO has received breakthrough therapy designation from the FDA as a potential treatment for patients with recurrent glioblastoma multiforme.

Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma Imaging

May 9th 2016

Although advances have been made in imaging techniques for patients with glioblastoma multiforme, new tools are needed to supplement standard imaging sequences.

Targeted Immunotherapy on Horizon for Brain Tumors

April 6th 2016

The future looks bright for immunotherapies and novel targeted approaches for patients with gliomas, many of which have already been developed for other types of cancer.

Rindopepimut Misses OS Endpoint in Phase III Glioblastoma Trial

March 7th 2016

Treatment with rindopepimut (Rintega) plus temozolomide failed to improve overall survival compared with temozolomide and a control for patients with newly diagnosed EGFRvIII-positive glioblastoma multiforme.

Enhancing Immune System May Boost Survival for Brain Cancer Patients

February 23rd 2016

Researchers at Washington University in St. Louis and elsewhere are focusing on lymphocytes, the essential effector cells in the immune response to cancer.

Novel Treatments in Glioblastoma: Looking Ahead

February 9th 2016